The binding strength of the developed peptibodies may seem much lower than that of the target-binding mAbs, but subsequent experiments testing internalization of peptibodyF4_1 and F4_3 into lung cancer cells with high and low levels of the FGFR1 expression demonstrated that such affinity is sufficient for selective peptibody delivery into cells. Here, FGFR1 is linked to lung carcinoma.